What is Antidote?
Established in 2010, Antidote operates at the intersection of technology and healthcare, aiming to streamline the complex process of medical research. The company leverages data-driven technologies, digital expertise, and a broad partner network to enhance patient engagement and facilitate high-quality trial recruitment. By integrating these elements with personalized patient and site services, Antidote, formerly known as TrialReach, has positioned itself as a key player in the digital health landscape, operating across the US and UK.
How much funding has Antidote raised?
Antidote has raised a total of $52.1M across 5 funding rounds:
Other Financing Round
$1.2M
Series A
$3.2M
Series B
$13.5M
Private Equity
$11M
Unspecified
$23.2M
Other Financing Round (2011): $1.2M with participation from Amadeus Capital Partners
Series A (2013): $3.2M led by Octopus Ventures and Amadeus Capital Partners
Series B (2015): $13.5M supported by Octopus Ventures and Amadeus Capital Partners
Private Equity (2017): $11M featuring Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures
Unspecified (2021): $23.2M backed by LBO France
Key Investors in Antidote
Octopus Ventures
Octopus Ventures is a prominent UK-based venture capital firm known for its investments in high-growth companies across various sectors, including digital health. They focus on providing capital and strategic support to businesses aiming for significant market impact.
Amadeus Capital Partners
Amadeus Capital Partners is a global technology venture capital firm that invests in high-growth companies from seed to later stages, with a particular interest in sectors like artificial intelligence and digital health.
Merck Global Health Innovation Fund
The Merck Global Health Innovation Fund is an investment arm of Merck & Co., Inc., dedicated to investing in companies that advance healthcare through innovative technologies and solutions, particularly in digital health and related fields.
What's next for Antidote?
The recent major strategic investment signals a new phase of growth and expansion for Antidote. This capital infusion is expected to fuel further development of its precision recruitment platform and broaden its reach within the medical research community. The company's focus on balancing technological innovation with a human-centric approach suggests a continued commitment to improving patient access to clinical trials, potentially leading to faster drug development and better health outcomes.
See full Antidote company page
